Southern California devicemaker Vertos Medical has been around a decade, and has a clinically validated treatment for lumbar spinal stenosis. It’s raised many dollars in venture financing, and is in the midst of a new equity round. This begs the question – when will Vertos IPO?
Vertos is aiming to raise $12 million, according to a regulatory filing, and has raised about half of that so far from 21 investors. The company has developed a treatment to allay symptoms of lumbar spinal stenosis, with a simple outpatient procedure that it’s commercializing in the U.S. and Europe.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s well-financed – it closed out a $23 million Series E in 2013, and has been around and raising funds since 2005.
Given the robust funding, the 10-year timeline and a wide spectrum of investors, this begs the question – when will Vertos secure an exit? It’s still raising cash, sure, but the product has already hit the market. It’s time.
Previous investors in Vertos have included ONSET Ventures, CHL Medical Partners, Foundation Medical Partners and Awelda Venture Partners.
Lumbar spinal stenosis – a narrowing of the spinal canal – is a common issue among those over 50, choking the nerves in that region and causing significant pain.
Vertos is conducting a clinical trial that compares its MILD procedure to epidural spinal injections. It’s projected to wrap up in December 2016. It’s already been tested out in 11 prior clinical trials.
[PHOTO: Wikimedia Commons]